What is NovaBay Pharmaceuticals Operating Cash Flow per Share?
NovaBay Pharmaceuticals's operating cash flow per share for the
three
months ended in Dec. 2023 was $-0.03.
NovaBay Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.48.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 40.80% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 35.30% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 42.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for NovaBay Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:
NBY'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -44.7 Med: 31.4 Max: 63.3
Current: 40.8
During the past 13 years, NovaBay Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 63.30% per year. The lowest was -44.70% per year. And the median was 31.40% per year.
NBY's 3-Year OCF Growth Rate is ranked better than 85.99% of 1235
companies
in the Biotechnology industry
Industry Median: 3.5
vs NBY: 40.80
NovaBay Pharmaceuticals Operating Cash Flow per Share Historical Data
The historical data trend for NovaBay Pharmaceuticals's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
NovaBay Pharmaceuticals Operating Cash Flow per Share Chart
Competitive Comparison of NovaBay Pharmaceuticals's Operating Cash Flow per Share
For the Biotechnology subindustry, NovaBay Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovaBay Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NovaBay Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where NovaBay Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.
NovaBay Pharmaceuticals Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
NovaBay Pharmaceuticals's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.48
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovaBay Pharmaceuticals Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of NovaBay Pharmaceuticals's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
NovaBay Pharmaceuticals (NovaBay Pharmaceuticals) Business Description
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare and skincare products. Its leading product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available direct to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NBY has been successfully added to your 